Use of Oral Corticosteroids to Treat HTLV-1-Associated Myelopathy (HAM) in São Paulo, Brazil
Background: During the development of human T-cell lymphotropic virus (HTLV-1)-associated myelopathy (HAM), the inflammatory phenomenon is very prominent and is a major factor in the outcome of the disease. The use of corticosteroids can modify their natural history, and in this study, we evaluated...
Main Authors: | Flavia Esper Dahy, Tatiane Assone, Rosa M. N. Marcusso, João V. Luisi de Moura, Michel E. J. Haziot, Jose E. Vidal, Jerusa Smid, Augusto C. Penalva de Oliveira, Jorge Casseb |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Microbiology Research |
Subjects: | |
Online Access: | https://www.mdpi.com/2036-7481/14/2/46 |
Similar Items
-
HTLV-1-Associated Myelopathy (HAM) Incidence in Asymptomatic Carriers and Intermediate Syndrome (IS) Patients
by: Rosa Maria do Nascimento Marcusso, et al.
Published: (2024-05-01) -
Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P)
by: Junji Yamauchi, et al.
Published: (2022-01-01) -
Progression of HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis after Pregnancy: A Case Series and Review of the Literature
by: Frederique A. Jacquerioz, et al.
Published: (2024-08-01) -
Small cells lung epidermoid carcinoma in a HTLV1-infected patient: case report and literature review
by: Flávia Esper Dahy, et al.
Published: (2021-04-01) -
The Barriers of Coping with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Content Analysis Study
by: Malihe Davoudi, et al.
Published: (2023-10-01)